Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ZP1848 in patients with short bowel syndrome
2015-002826-38Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Oct 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of glepaglutide in short bowel syndrome (SBS) (3 arms), sponsored by Zealand Pharma. Primary endpoint: Change in wet weight of ostomy output or diarrhea. Started Oct 2015; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2015-002826-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002826-38.